CD274 and non-small cell lung carcinoma: According to clinical studies showing a positive association, the United States (US) Food and Drug Administration (FDA) approved pembrolizumab for the treatment of PD-L1-positive non-small cell lung cancer (NSCLC), gastric or gastroesophageal junction cancer, and cervical cancer in 2015, 2017, and 2018, respectively.